Trial Profile
A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 22 Sep 2021
Price :
$35
*
At a glance
- Drugs KO 947 (Primary)
- Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Kura Oncology
- 22 Jan 2021 Status changed from active, no longer recruiting to discontinued.
- 19 Jun 2020 Planned End Date changed from 30 Aug 2020 to 31 Dec 2020.
- 19 Jun 2020 Planned primary completion date changed from 29 Feb 2020 to 31 Dec 2020.